<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the proper treatment for resectable <z:e sem="disease" ids="C1332128" disease_type="Neoplastic Process" abbrv="">peritoneal carcinomatosis</z:e> (PC) </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to evaluate the postoperative course and long-term outcome of repeat CS (reCS) plus repeat HIPEC (reHIPEC) in patients with <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e>, after primary CS plus primary HIPEC </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: From 2004 to 2012 85 patients were subjected to primary CS + HIPEC </plain></SENT>
<SENT sid="3" pm="."><plain>Fourteen of those patients developed recurrent PC and were subjected to reCS+reHIPEC during the same time period </plain></SENT>
<SENT sid="4" pm="."><plain>Eligibility criteria included limited extent of the <z:e sem="disease" ids="C0031142" disease_type="Disease or Syndrome" abbrv="">peritoneal disease</z:e>, and interval of more than 12 months from the primary CS+HIPEC </plain></SENT>
<SENT sid="5" pm="."><plain>The origins of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (n=7) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (n=3), <z:mpath ids='MPATH_303'>pseudomyxoma peritonei</z:mpath> (n=3), and uterine <z:hpo ids='HP_0100242'>sarcoma</z:hpo> (n=1) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: At second laparotomy, mean <z:e sem="disease" ids="C0153467" disease_type="Neoplastic Process" abbrv="">peritoneal cancer</z:e> index (PCI) was 5.3 + 2.8 </plain></SENT>
<SENT sid="7" pm="."><plain>Among the 14 procedures, HIPEC was used in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>The postoperative mortality was 0% and grade 3-4 postoperative complications occurred in 4 patients </plain></SENT>
<SENT sid="9" pm="."><plain>The overall 1-, 2- and 3- year overall survival rate was 90, 40 and 30%, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: ReCS+reHIPEC is feasible and yields an accepted survival in highly selected patients </plain></SENT>
</text></document>